Business
PDS Biotechnology journal publication
PDS Biotechnology journal publication.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 3115Z NetScientific PLC 16 May 2019 \n\n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\")\n \nPDS Biotechnology journal publication\n \nNetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq:PDSB) has announced a peer-reviewed publication supporting the novel mechanisms of action of PDS's proprietary Versamune® platform in cancer immunotherapy. \n \nThe article \"Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response\" was published online in the Journal of Immunology, and describes the way PDS' Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack. The article will appear in print in the June 2019 issue of the Journal.\n \nNetScientific holds 8.15% of PDS on a fully diluted basis.\nThe full text of the announcement released by PDS Biotechnology Corporation can be found below.\n# # #\n \nFor more information, please contact:\n \n\n\n\n NetScientific\n Ian Postlethwaite, CEO and CFO\n\n\nTel: 020 3514 1800\n\n\n\n\n \nWH Ireland (NOMAD and Broker)\nChris Fielding / Jessica Cave\n\n\n Tel: 020 7220 1666\n\n\n\n \nPDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy\n \nPDS Biotechnology Corporation (\"PDS Biotechnology\") (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multifunctional immunotherapeutic products, today announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune® platform in cancer immunotherapy. The article \"Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response\" was published online on May 3, 2019 in the Journal of Immunology, and describes the way PDS' Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while si...